• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.

作者信息

Deng Lucy, Lopez Laura K, Glover Catherine, Cashman Patrick, Reynolds Renee, Macartney Kristine, Wood Nicholas

机构信息

National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.

School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia.

出版信息

JAMA. 2023 Jun 20;329(23):2091-2094. doi: 10.1001/jama.2023.7683.

DOI:10.1001/jama.2023.7683
PMID:37145654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10282881/
Abstract
摘要

相似文献

1
Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.接种安卡拉痘苗病毒-巴伐利亚北欧公司（MVA-BN）疫苗预防猴痘后的短期不良事件。
JAMA. 2023 Jun 20;329(23):2091-2094. doi: 10.1001/jama.2023.7683.
2
Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.儿童单次接种改良安卡拉-巴伐利亚北欧天花疫苗后的安全性、反应原性和免疫应答的早期评估：国家疫情应对。
Lancet Infect Dis. 2023 Sep;23(9):1042-1050. doi: 10.1016/S1473-3099(23)00270-0. Epub 2023 Jun 16.
3
Human Monkeypox Virus Infection in the Immediate Period After Receiving Modified Vaccinia Ankara Vaccine.接种安卡拉痘苗病毒疫苗后短期内的人类猴痘病毒感染
JAMA. 2022 Nov 22;328(20):2064-2067. doi: 10.1001/jama.2022.18320.
4
Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.描述澳大利亚猴痘疫情后，天花疫苗和 MVA-BN 疫苗的急性抗体反应。
J Med Virol. 2024 Jan;96(1):e29407. doi: 10.1002/jmv.29407.
5
Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.对在有感染猴痘风险的加拿大人群中接种改良安卡拉痘苗-巴伐利亚北欧株（MVA-BN）后的不良事件进行前瞻性监测：加拿大免疫研究网络研究。
Vaccine. 2024 Jan 25;42(3):535-540. doi: 10.1016/j.vaccine.2023.12.068. Epub 2024 Jan 9.
6
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine.MVA-BN 的冻干和液冻制剂作为天花和猴痘疫苗的等效性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2384189. doi: 10.1080/21645515.2024.2384189. Epub 2024 Aug 22.
7
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.单次和双剂量接种改良安卡拉牛痘疫苗-巴伐利亚北欧株可诱导持久的 B 细胞记忆应答，与复制天花疫苗相当。
J Infect Dis. 2023 May 12;227(10):1203-1213. doi: 10.1093/infdis/jiac455.
8
Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?单剂量的安卡拉痘苗病毒-北欧巴伐利亚疫苗能否预防猴痘？
Lancet Infect Dis. 2023 Jul;23(7):768-769. doi: 10.1016/S1473-3099(23)00115-9. Epub 2023 Mar 13.
9
Modified vaccinia Ankara-Bavarian Nordic vaccine against mpox in children.用于儿童的改良安卡拉痘苗-巴伐利亚北欧疫苗预防猴痘。
Lancet Infect Dis. 2023 Sep;23(9):989-990. doi: 10.1016/S1473-3099(23)00345-6. Epub 2023 Jun 16.
10
Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.2022 年 6 月至 8 月，法国里昂一项针对改良安卡拉痘苗接种以预防猴痘（曾用名：猴痘）的暴露后疫苗接种效果的回顾性观察研究。
Euro Surveill. 2022 Dec;27(50). doi: 10.2807/1560-7917.ES.2022.27.50.2200882.

引用本文的文献

1
Target Trial Emulation of the Modified Vaccinia Ankara-Bavarian Nordic Vaccine for Pre-Exposure Mpox Prevention in At-Risk Populations.用于高危人群暴露前预防猴痘的改良安卡拉痘苗-巴伐利亚北欧疫苗的目标试验模拟
Vaccines (Basel). 2025 May 30;13(6):594. doi: 10.3390/vaccines13060594.
2
Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein.与痘苗病毒A35R蛋白相比，基于A35R-Fc的嵌合蛋白具有增强的免疫原性和亲和力。
Viruses. 2025 Jan 16;17(1):116. doi: 10.3390/v17010116.
3
[Descriptive study of events allegedly attributable to mpox vaccination in Brazil in 2023].[2023年巴西疑似因猴痘疫苗接种导致的事件描述性研究]
Cad Saude Publica. 2024 Nov 4;40(10):e00006624. doi: 10.1590/0102-311XPT006624. eCollection 2024.
4
Stigmatization and Preferences in Monkeypox Vaccine Regimens.猴痘疫苗方案中的污名化和偏好。
Arch Sex Behav. 2024 Nov;53(10):3825-3834. doi: 10.1007/s10508-024-02975-6. Epub 2024 Aug 21.
5
First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response.韩国首个全国性猴痘疫苗接种计划：对加强公共卫生应对的启示。
J Korean Med Sci. 2024 Aug 19;39(32):e235. doi: 10.3346/jkms.2024.39.e235.
6
Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.全球视角下的天花疫苗对猴痘的效果、保护作用、安全性和交叉免疫原性：一项综合的荟萃分析和系统评价。
Emerg Microbes Infect. 2024 Dec;13(1):2387442. doi: 10.1080/22221751.2024.2387442. Epub 2024 Aug 16.
7
Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea.在韩国，经皮接种 JYNNEOS 进行猴痘疫苗接种后的不良反应。
J Korean Med Sci. 2024 Mar 4;39(8):e100. doi: 10.3346/jkms.2024.39.e100.
8
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.根据既往天花疫苗接种情况和HIV感染情况，评估安卡拉痘苗病毒（modified vaccinia Ankara）暴露前接种预防猴痘的免疫原性和反应原性：前瞻性队列研究
EClinicalMedicine. 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb.
9
Safety of Monkeypox Vaccine Using Active Surveillance, Two-Center Observational Study in Italy.使用主动监测的猴痘疫苗安全性：意大利的一项两中心观察性研究
Vaccines (Basel). 2023 Jun 27;11(7):1163. doi: 10.3390/vaccines11071163.

本文引用的文献

1
The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.澳大利亚 COVID-19 疫苗的短期安全性：AusVaxSafety 主动监测，2021 年 2 月至 8 月。
Med J Aust. 2022 Aug 15;217(4):195-202. doi: 10.5694/mja2.51619. Epub 2022 Jul 4.
2
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.三种连续生产批次非复制天花疫苗 MVA 的免疫原性和安全性：一项随机、双盲、安慰剂对照 III 期临床试验。
PLoS One. 2018 Apr 13;13(4):e0195897. doi: 10.1371/journal.pone.0195897. eCollection 2018.
3
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.冻干与液体形式的改良安卡拉痘苗（MVA）制剂以及在未接触过痘苗的健康受试者中皮下与皮内给药途径的比较。
Vaccine. 2015 Sep 22;33(39):5225-34. doi: 10.1016/j.vaccine.2015.06.075. Epub 2015 Jul 2.